Labcorp — Oct 28, 2025 release

8 versus $3.50 • Updated Full-Year Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance: ◦ Revenue guidance of 7.4% to 8.0%; midpoint lowered 40 bps due to currency and acquisition timing ◦ Adjusted EPS range of $16.15 to $16.50; midpoint raised by $0.05 ◦ Free Cash Flow range of $1.17 billion to $1.29 billion; midpoint raised by $25 million • Signed several strategic agreements with health systems and regional/local laboratories • Advanced business in high-growth specialty testing areas, including oncology and neurology • Introduced Labcorp Test Finder and new digital pathology, cytology and microbiology capabilities BURLINGTON, N.C., October 28, 2025 – Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the third quarter ended September 30, 2025 and updated full-year guidance. “Labcorp’s third-quarter performance reflects continued momentum in our Diagnostics and Central Laboratory businesses, resulting in strong revenue growth and margin improvement,” said Adam Schechter, Chairman and CEO of Labcorp. “We advanced our strategy by forming new partnerships with health systems and regional laboratories, introducing innovative tests in key specialty areas and leveraging science and technology to improve customer experience and operational efficiency. Our performance led to double-digit adjusted EPS growth and strong cash flow in the quarter. W